AMD 2017: A Review of Treatment Guidelines and the Role of Appropriate Therapy - Part 3
Overview
Supported by an educational grant from Regeneron Pharmaceuticals, Inc. Learning Objectives
Upon completion of this activity, participants will be better able to: - Assess the most recent monotherapy and combination therapy clinical study evidence using available anti-VEGF therapies for common retinal diseases, including AMD.
- Discuss the ocular and systemic effects of anti-VEGF therapies and how to educate patients on appropriate expectations.
- Develop plans to initiate treatment for conditions such as AMD using anti-VEGF agents as well as better understand when to change therapeutic strategies.
Accreditation
Accreditation and Designation Statement This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education LLC,Retina Today and New Retina MD. Evolve Medical Education LLC designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Off Label Discussion This educational activity might contain discussion of evidence-based and/or investigational uses of agents that are not indicated by the FDA. For additional information about approved uses, please refer to the official prescribing information. Faculty and Disclosures
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.- SriniVas Sadda, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Carl Zeiss Meditec and Optos. Grant/Research Support: Carl Zeiss Meditec and Optos.
- Richard F. Spaide, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Topcon Corporation.
- Rishi P. Singh, MD, Peer Reviewer, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Allergan Plc; Carl Zeiss Meditec; Genentech, Inc; Optos; Regeneron Pharmaceuticals, Inc; and Shire Plc. Grant/Research Support: Alcon; Apellis Pharmaceuticals; Genentech, Inc; and Regeneron Pharmaceuticals, Inc.
- Cheryl Cavanaugh, MS, Evolve Medical Education LLC; and Michelle Dalton, Writer, have no relevant commercial interests to disclose.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Yewlin E. Chee, MD
Camila Ventura MD, PhD
Edward Wood, MD
Tony Capone Jr, MD
Katherine E. Talcott, MD
Nassim Abreu, MD
- CME/CE In-Person & Virtual Event
Treating Outside the Box: New Pathways to Retinal Vascular Stability
July 17, 2026
Montreal Katherine E. Talcott, MD
Christina Y. Weng, MD, MBA, FASRS
Roger A. Goldberg, MD, MBA
Katherine E. Talcott, MD
Roger A. Goldberg, MD, MBA
